Total pharma deals worth $21.11bn were announced during Q4 2018, according to GlobalData’s deals database.


The value marked a decrease of 6.32% over the previous quarter and a drop of 64.84% when compared with the last four-quarter average of $60.07bn.

In terms of number of deals, the sector saw a drop of 7.18% over the last four-quarter average with 388 deals against the average of 418 deals.

In value terms, North America led the activity with deals worth $16.64bn.

The top announced deal, as tracked by GlobalData, in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The article considers only announced and completed deals from the GlobalData Financial Deals database and excludes all terminated and rumoured deals. GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.